IDEAYA Biosciences entered into a clinical collaboration agreement with AstraZeneca on April 8, 2026, to evaluate IDE849 in combination with Imfinzi for extensive-stage small cell lung cancer.
Key takeaways
IDEAYA entered a clinical collaboration with AstraZeneca to evaluate IDE849 combined with Imfinzi in extensive-stage SCLC.
IDEAYA will sponsor the clinical combination study, while AstraZeneca will supply Imfinzi.
IDE849 is an investigational DLL3 TOP1 antibody-drug conjugate being studied as a potential first-in-class therapy.
The collaboration targets extensive-stage small cell lung cancer, an area with significant unmet medical need.
IDEAYA is advancing a global Phase 1 trial for IDE849 in DLL3-upregulated tumors including SCLC, NECs, NETs, and melanoma.
DLL3 is upregulated in multiple solid tumors but has limited expression in normal tissues, making it a promising therapeutic target.